I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.

BBIO Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 24.66%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $155,346,267.36

BridgeBio Pharma Insider Trading History Chart

BridgeBio Pharma Share Price & Price History

^$27.44

▲ +0.86 (3.24%)

As of 12/4/2024 02:27 PM ET

Days: 30 | 90 | 365

Strange: Why is Amazon suddenly yielding 39.70%?

From Investors Alley | Ad

Something big is happening with Amazon stock… While most investors collect ZERO dividends from Amazon… A small group just discovered a "backdoor" way to collect yields up to 39.70%!

Click here to see this breakthrough before everyone else →

BridgeBio Pharma Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/19/2024	Brian C. Stephenson	CFO	Sell	4,156	$22.41	$93,135.96	93,758
11/19/2024	Neil Kumar	CEO	Sell	27,389	$22.41	$613,787.49	4,897,443
9/13/2024	Genetic Disorder L.P. Kkr	Major Shareholder	Sell	5,800,000	$25.75	$149,350,000.00	25,260,971
8/19/2024	Brian C. Stephenson	CFO	Sell	4,155	$24.69	$102,586.95	85,192
8/19/2024	Neil Kumar	CEO	Sell	27,389	$24.69	$676,234.41	4,897,443
6/3/2024	Randal W. Scott	Director	Sell	1,000	$28.84	$28,840.00	5,500
3/1/2024	Randal W. Scott	Director	Sell	2,500	$34.00	$85,000.00	6,500
1/16/2024	Hannah Valantine	Director	Sell	2,915	$37.97	$110,682.55	1,764
12/26/2023	Frank McCormick	Director	Sell	100,000	$42.06	$4,206,000.00	627,689
12/18/2023	Randal W. Scott	Director	Sell	2,000	$40.00	$80,000.00	9,000
8/17/2023	Brian C. Stephenson	CFO	Sell	22,683	$28.59	$648,506.97	36,710
8/17/2023	Neil Kumar	CEO	Sell	51,552	$28.59	$1,473,871.68	4,813,197
7/18/2023	Global Investors Lp Viking	Major Shareholder	Sell	1,500,000	$35.00	$52,500,000.00	25,120,991
5/17/2023	Brian C. Stephenson	CFO	Sell	24,424	$14.01	$342,180.24	36,408
5/17/2023	Neil Kumar	CEO	Sell	51,552	$14.01	$722,243.52	4,813,197
4/5/2023	Brian C. Stephenson	CFO	Sell	55,500	$15.45	$857,475.00	101,337
4/5/2023	Neil Kumar	CEO	Sell	120,000	$15.46	$1,855,200.00	1,132,722
3/3/2023	Brian C. Stephenson	CFO	Sell	62,692	$10.96	$687,104.32	156,837
3/3/2023	Neil Kumar	CEO	Sell	120,000	$10.96	$1,315,200.00	1,252,722
2/17/2023	Brian C. Stephenson	CFO	Sell	17,717	$12.70	$225,005.90	219,529
2/17/2023	Neil Kumar	CEO	Sell	44,798	$12.70	$568,934.60	4,813,197
2/3/2023	Brian C. Stephenson	CFO	Sell	61,040	$11.01	$672,050.40	219,184
2/3/2023	Neil Kumar	CEO	Sell	120,000	$11.01	$1,321,200.00	1,372,722
1/5/2023	Brian C. Stephenson	CFO	Sell	61,040	$7.67	$468,176.80	280,224
1/5/2023	Neil Kumar	CEO	Sell	120,000	$7.67	$920,400.00	1,492,722
11/17/2022	Brian C. Stephenson	CFO	Sell	19,678	$9.40	$184,973.20	341,264
11/17/2022	Neil Kumar	CEO	Sell	34,640	$9.40	$325,616.00	4,813,197
3/14/2022	Douglas A. Dachille	Director	Buy	10,000	$8.19	$81,900.00
1/4/2022	Douglas A. Dachille	Director	Buy	5,000	$16.82	$84,100.00
12/30/2021	Ronald J. Daniels	Director	Buy	10,402	$14.34	$149,164.68
12/28/2021	Ronald J. Daniels	Director	Buy	11,745	$12.73	$149,513.85

Media Is Mocking Elon, But Wait Until They See This Demo

From Brownstone Research | Ad

Elon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it.

Click here to watch this demo and decide for yourself.

SEC Filings (Institutional Ownership Changes) for BridgeBio Pharma (NASDAQ:BBIO)

99.85% of BridgeBio Pharma stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

BridgeBio Pharma Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
11/16/2024	Geode Capital Management LLC	3,413,949	$86.94M	0.0%	+3.8%	1.806%
11/15/2024	Frazier Life Sciences Management L.P.	3,760,457	$95.74M	3.8%	+3.5%	1.990%
11/15/2024	Barclays PLC	545,008	$13.88M	0.0%	+31.9%	0.288%
11/15/2024	Y Intercept Hong Kong Ltd	13,279	$0.34M	0.0%	N/A	0.007%
11/15/2024	Wellington Management Group LLP	69,586	$1.77M	0.0%	-95.3%	0.037%
11/15/2024	Sphera Funds Management LTD.	842,644	$21.45M	3.4%	-24.4%	0.446%
11/15/2024	Quarry LP	10,000	$0.26M	0.1%	+33.3%	0.005%
11/15/2024	Polar Asset Management Partners Inc.	50,500	$1.29M	0.0%	N/A	0.027%
11/15/2024	Melqart Asset Management UK Ltd	403,485	$10.27M	0.9%	+31.0%	0.213%
11/15/2024	Ikarian Capital LLC	285,613	$7.27M	1.0%	-15.5%	0.151%
11/15/2024	Janus Henderson Group PLC	4,818,012	$122.66M	0.1%	+11.7%	2.549%
11/15/2024	HighVista Strategies LLC	69,054	$1.76M	0.6%	+54.9%	0.037%
11/15/2024	Erste Asset Management GmbH	140,225	$3.50M	0.0%	N/A	0.075%
11/14/2024	Bellevue Group AG	10,400	$0.27M	0.0%	-18.8%	0.006%
11/14/2024	Hhlr Advisors LTD.	1,023,950	$26.07M	0.6%	-26.4%	0.545%
11/14/2024	Rockefeller Capital Management L.P.	41,259	$1.05M	0.0%	+11.7%	0.022%
11/13/2024	The Manufacturers Life Insurance Company	1,532,224	$39.01M	0.0%	-0.2%	0.815%
11/13/2024	Dynamic Technology Lab Private Ltd	15,029	$0.38M	0.0%	N/A	0.008%
11/13/2024	Daiwa Securities Group Inc.	31,709	$0.81M	0.0%	-11.2%	0.017%
11/12/2024	Algert Global LLC	136,447	$3.47M	0.1%	+144.3%	0.073%
11/12/2024	Eagle Asset Management Inc.	11,201	$0.30M	0.0%	-95.8%	0.006%
11/12/2024	Charles Schwab Investment Management Inc.	1,284,802	$32.71M	0.0%	+8.0%	0.683%
11/12/2024	Massachusetts Financial Services Co. MA	737,367	$18.77M	0.0%	+23.3%	0.392%
11/9/2024	Primecap Management Co. CA	906,724	$23.09M	0.0%	-2.2%	0.482%
11/9/2024	Intech Investment Management LLC	44,623	$1.14M	0.0%	N/A	0.024%
11/8/2024	Advisors Asset Management Inc.	4,576	$0.12M	0.0%	+56.1%	0.002%
11/8/2024	Connor Clark & Lunn Investment Management Ltd.	12,148	$0.31M	0.0%	N/A	0.006%
11/8/2024	Jennison Associates LLC	30,119	$0.77M	0.0%	N/A	0.016%
11/8/2024	B. Metzler seel. Sohn & Co. Holding AG	36,603	$0.93M	0.0%	N/A	0.019%
11/7/2024	First Turn Management LLC	399,781	$10.18M	1.6%	N/A	0.213%
11/7/2024	Quest Partners LLC	31,173	$0.79M	0.1%	+134.0%	0.017%
11/7/2024	Swiss National Bank	219,300	$5.58M	0.0%	+1.1%	0.117%
11/6/2024	Mizuho Markets Americas LLC	87,180	$2.22M	0.0%	+3.8%	0.046%
11/6/2024	Royce & Associates LP	121,955	$3.11M	0.0%	N/A	0.065%
11/5/2024	Victory Capital Management Inc.	377,182	$9.60M	0.0%	-1.4%	0.201%
11/5/2024	WCM Investment Management LLC	263,679	$6.58M	0.0%	+49.2%	0.140%
11/4/2024	State of New Jersey Common Pension Fund D	76,586	$1.95M	0.0%	+13.7%	0.041%
10/31/2024	Principal Financial Group Inc.	1,145,123	$29.16M	0.0%	+1.8%	0.609%
10/29/2024	Fernwood Investment Management LLC	261,735	$6.66M	2.2%	+2.4%	0.139%
10/29/2024	Emerald Advisers LLC	1,103,508	$28.10M	1.1%	+65.6%	0.587%
10/29/2024	Emerald Mutual Fund Advisers Trust	751,355	$19.13M	1.0%	+50.8%	0.400%
10/25/2024	China Universal Asset Management Co. Ltd.	36,165	$0.92M	0.1%	+64.5%	0.019%
10/23/2024	Mirae Asset Global Investments Co. Ltd.	6,801	$0.17M	0.0%	+21.7%	0.004%
10/23/2024	Values First Advisors Inc.	2,237	$57K	0.0%	N/A	0.001%
10/23/2024	Assenagon Asset Management S.A.	24,134	$0.61M	0.0%	-90.2%	0.013%
10/23/2024	Moody Aldrich Partners LLC	123,509	$3.15M	0.6%	-1.8%	0.066%
10/23/2024	Hennion & Walsh Asset Management Inc.	38,043	$0.97M	0.0%	-2.7%	0.020%
10/19/2024	Allspring Global Investments Holdings LLC	5,322	$0.14M	0.0%	+17.7%	0.003%
10/11/2024	Creative Planning	31,264	$0.77M	0.0%	N/A	0.017%
10/8/2024	CWM LLC	3,442	$88K	0.0%	+132.9%	0.002%
10/7/2024	Diversified Trust Co	36,772	$0.94M	0.0%	+3.0%	0.020%
10/5/2024	Handelsbanken Fonder AB	32,550	$0.83M	0.0%	+17.7%	0.017%
9/4/2024	Ghisallo Capital Management LLC	33,750	$0.86M	0.1%	-50.0%	0.018%
8/16/2024	Perceptive Advisors LLC	1,215,346	$30.79M	0.7%	-13.9%	0.649%
8/16/2024	Quarry LP	7,500	$0.19M	0.0%	+27.1%	0.004%
8/16/2024	Capital Impact Advisors LLC	13,925	$0.35M	1.0%	-5.7%	0.007%
8/16/2024	Algert Global LLC	55,848	$1.42M	0.0%	-37.5%	0.030%
8/16/2024	Frazier Life Sciences Management L.P.	3,632,604	$92.01M	4.3%	+6.4%	1.941%
8/15/2024	Susquehanna Fundamental Investments LLC	167,839	$4.25M	0.1%	N/A	0.090%
8/15/2024	Lion Point Capital LP	49,000	$1.24M	2.3%	N/A	0.026%
8/15/2024	The Manufacturers Life Insurance Company	1,534,972	$38.88M	0.0%	+40.5%	0.820%
8/15/2024	AQR Capital Management LLC	125,160	$3.17M	0.0%	-3.7%	0.067%
8/14/2024	Squarepoint Ops LLC	252,793	$6.40M	0.0%	N/A	0.135%
8/14/2024	Marshall Wace LLP	30,849	$0.78M	0.0%	N/A	0.016%
8/14/2024	Xponance Inc.	8,871	$0.23M	0.0%	+25.5%	0.005%
8/14/2024	HighVista Strategies LLC	44,572	$1.13M	0.4%	-21.2%	0.024%
8/14/2024	ProShare Advisors LLC	27,177	$0.69M	0.0%	-18.3%	0.015%
8/14/2024	Profund Advisors LLC	51,029	$1.29M	0.0%	+1.1%	0.027%
8/13/2024	Ensign Peak Advisors Inc	1,646,202	$41.70M	0.1%	+44.5%	0.880%
8/12/2024	XTX Topco Ltd	12,096	$0.31M	0.0%	-26.9%	0.006%
8/12/2024	Vanguard Personalized Indexing Management LLC	10,202	$0.26M	0.0%	+18.8%	0.005%
8/12/2024	Amalgamated Bank	4,863	$0.12M	0.0%	+24.7%	0.003%
8/12/2024	E Fund Management Co. Ltd.	16,496	$0.42M	0.0%	+12.1%	0.009%
8/9/2024	Dimensional Fund Advisors LP	73,230	$1.86M	0.0%	+5.2%	0.039%
8/9/2024	Massachusetts Financial Services Co. MA	598,263	$15.15M	0.0%	+57.9%	0.320%
8/8/2024	Federated Hermes Inc.	4,500	$0.11M	0.0%	-94.3%	0.002%
8/8/2024	American Century Companies Inc.	1,096,734	$27.78M	0.0%	+20.0%	0.586%
8/8/2024	State of New Jersey Common Pension Fund D	67,361	$1.71M	0.0%	-15.8%	0.036%
8/7/2024	Headlands Technologies LLC	1,905	$48K	0.0%	N/A	0.001%
8/7/2024	Daiwa Securities Group Inc.	35,709	$0.90M	0.0%	+5,393.7%	0.019%
8/6/2024	Quest Partners LLC	13,324	$0.34M	0.0%	N/A	0.007%
8/6/2024	Emerald Advisers LLC	666,344	$16.88M	0.7%	-4.7%	0.356%
8/6/2024	Emerald Mutual Fund Advisers Trust	498,254	$12.62M	0.7%	-0.4%	0.266%
8/5/2024	Arizona State Retirement System	30,857	$0.78M	0.0%	+7.6%	0.016%
8/5/2024	Victory Capital Management Inc.	382,717	$9.69M	0.0%	+9.9%	0.205%
8/1/2024	Rhumbline Advisers	221,403	$5.61M	0.0%	+19.5%	0.118%
7/31/2024	Mizuho Markets Americas LLC	83,982	$2.13M	0.1%	+13.0%	0.045%
7/29/2024	Principal Financial Group Inc.	1,125,145	$28.50M	0.0%	+4.8%	0.601%
7/29/2024	Panagora Asset Management Inc.	727,963	$18.44M	0.1%	+75.3%	0.389%
7/29/2024	Zurcher Kantonalbank Zurich Cantonalbank	25,072	$0.64M	0.0%	+14.2%	0.013%
7/29/2024	Bfsg LLC	1,240	$31K	0.0%	+175.6%	0.001%
7/20/2024	China Universal Asset Management Co. Ltd.	21,984	$0.56M	0.1%	-34.9%	0.012%
7/20/2024	Nisa Investment Advisors LLC	31,878	$0.81M	0.0%	-18.2%	0.017%
7/20/2024	Hennion & Walsh Asset Management Inc.	39,099	$0.99M	0.1%	-72.9%	0.021%
7/18/2024	Assenagon Asset Management S.A.	246,895	$6.25M	0.0%	+3,429.6%	0.132%
7/16/2024	Diversified Trust Co	35,713	$0.91M	0.0%	+28.9%	0.019%
7/2/2024	Transcend Capital Advisors LLC	13,500	$0.34M	0.0%	N/A	0.007%
5/17/2024	Zimmer Partners LP	73,200	$2.26M	0.0%	+12.6%	0.039%
5/17/2024	Comerica Bank	38,514	$1.19M	0.0%	+3,013.5%	0.021%
5/16/2024	California State Teachers Retirement System	105,596	$3.27M	0.0%	+7.3%	0.056%

Data available starting January 2016

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

Today's Range

Now: $27.44

$26.30

$27.80

50 Day Range

MA: $25.08

$22.35

$27.49

52 Week Range

Now: $27.44

$21.62

$44.32

Volume

673,952 shs

Average Volume

1,911,751 shs

Market Capitalization

$5.19 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.08

Who are the company insiders with the largest holdings of BridgeBio Pharma?: BridgeBio Pharma's top insider investors include:
Genetic Disorder LP Kkr (Major Shareholder)
Global Investors Lp Viking (Major Shareholder)
Neil Kumar (CEO)
Frank Mccormick (Director)
Brian C Stephenson (CFO)
Randal W Scott (Director)
Hannah Valantine (Director)
Learn More about top insider investors at BridgeBio Pharma.
Who are the major institutional investors of BridgeBio Pharma?: BridgeBio Pharma's top institutional investors include:
Janus Henderson Group PLC — 2.55%
Frazier Life Sciences Management L.P. — 1.99%
Geode Capital Management LLC — 1.81%
The Manufacturers Life Insurance Company — 0.81%
Charles Schwab Investment Management Inc. — 0.68%
Principal Financial Group Inc. — 0.61%
Learn More about top institutional investors of BridgeBio Pharma stock.
Which institutional investors are selling BridgeBio Pharma stock?: Within the previous quarter, BBIO stock was sold by these institutional investors:
Wellington Management Group LLP
Hhlr Advisors LTD.
Sphera Funds Management LTD.
Eagle Asset Management Inc.
Assenagon Asset Management S.A.
Jane Street Group LLC
Ikarian Capital LLC
Primecap Management Co. CA
Within the previous year, company insiders that have sold BridgeBio Pharma company stock include:
Genetic Disorder LP Kkr (Major Shareholder)
Global Investors Lp Viking (Major Shareholder)
Neil Kumar (CEO)
Frank Mccormick (Director)
Brian C Stephenson (CFO)
Randal W Scott (Director)
Learn More investors selling BridgeBio Pharma stock.
Which institutional investors are buying BridgeBio Pharma stock?: During the last quarter, BBIO stock was purchased by institutional investors including:
Janus Henderson Group PLC
Emerald Advisers LLC
First Turn Management LLC
Emerald Mutual Fund Advisers Trust
Erste Asset Management GmbH
Massachusetts Financial Services Co. MA
Barclays PLC
Frazier Life Sciences Management L.P.